Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.37 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912591 | 0.76 | SMN1; SMN2 (0.31) | SMN1; SMN2NEK2 | |
| SCHEMBL13113028 | 0.76 | — | — | |
| SCHEMBL12843938 | 0.73 | HDAC1 (0.33) | OTUD7BPYGBHDAC1 | |
| Hydantoin SCHEMBL5708042 | 0.72 | CRBN (0.35) | — | |
| SCHEMBL19382190 | 0.70 | OTUD7B (0.32) | OTUD7BPYGB | |
| SCHEMBL1508957 | 0.70 | OTUD7B (0.53) | OTUD7BPYGBNEK2 | |
| SCHEMBL6467970 | 0.68 | POLB (0.38) | TSHRNPSR1LMNA | |
| SCHEMBL22032447 | 0.68 | ALDH1A1 (0.45) | OTUD7BTSHRKDM4ELMNA | |
| SCHEMBL22032445 | 0.68 | ALDH1A1 (0.45) | OTUD7BTSHRKDM4ELMNA | |
| SCHEMBL14446948 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283434-A1 | NK1 ANTAGONISTS | OPKO HEALTH INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9688693-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| CN-105367505-A | Novel synthetic method of 3,6-dimethly-2,5-dioxopiperazine | SULI PHARMACEUTICAL TECH JIANGYIN CO LTD | 2016-03-02 | — | — | CN | disclosed |
| US-20140336158-A1 | NK1 ANTAGONISTS | TERSERA THERAPEUTICS LLC | 2014-11-13 | — | — | US | disclosed |
| US-8796299-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| EP-1463716-B1 | PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS | SCHERING CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-1995021283-A1 | PROCESS FOR BLEACHING TEXTILES | WARWICK INTERNATIONAL GROUP LIMITED (GB) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283434-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | OTUD7B 4811/4885PYGB 2313/4885SMN1; SMN2 3970/4885 |
| US-20140336158-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | OTUD7B 4811/4885PYGB 2313/4885SMN1; SMN2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.